Stricter treat-to-target in RA does not result in less radiographic progression: a longitudinal analysis in RA BIODAM
Authors' conclusion
In this daily practice cohort, following T2T principles more meticulously did not result in less radiographic progression than a somewhat more lenient attitude towards T2T.
Study context
- Population
- Patients with active RA from 10 countries starting/changing csDMARDs or bDMARDs, with treat-to-target (T2T) intensification pursued (RA-BIODAM cohort)76% female
- Participants
- 511 patients
- Exposure
- DAS44-T2T followed at 2 or 1 vs 0 visits per 3-month interval
- Outcome
- Change in SvdH score, assessed every 6 months
- Follow-up
- 2 years
Methodological detailslongitudinal analysis, daily clinical practice, multinational (10 countries), generalized estimating equations
- Longitudinal analysis
- Daily clinical practice
- Multinational (10 countries)
- Generalized estimating equations
Main finding
As reported in the abstract
Change in SvdH score in the same 6-month interval
Parameter estimate
+0.15 units
95% CI −0.04 to 0.33
T2T 2 VISITS
Parameter estimate
+0.08 units
95% CI −0.06 to 0.22
T2T 1 VISIT
Observational data: associations, not effects.
Further findings
2-year Sharp-van der Heijde (SvdH) progression, whole cohort
- Mean 2-year SvdH progression (SD), units
- 2.2 (4.1)
- Median 2-year SvdH progression, unit
- 1
Progression in the subsequent 6-month interval
- Stricter T2T did not reduce progression in the subsequent 6-month interval
Original publication
Stricter treat-to-target in RA does not result in less radiographic progression: a longitudinal analysis in RA BIODAM. Rheumatology (Oxford). Published 16 January 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →